Bonesupport Holding Ab · OMXSTO:BONEX
Bonesupport Holding Ab — Q4 2023 Earnings Presentation
14 slides from Bonesupport Holding Ab's earnings presentation, Feb 15, 2024
Slide 1: BONESUPPORT Q4 (2023) Report
BONESUPPORT Q4 (2023) Report February 15, 2024 Emil Billbäck, CEO Håkan Johansson, CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: BONESUPPORT – Fourth quarter report 2023
BONESUPPORT – Fourth quarter report 2023 Q4 2023: • Net sales SEK 173 m, growth: +67% versus Q3 2022, (+60% in constant exchange rates, CER) • Operating result (before accounting effects of incentive programs): SEK 11 m (SEK -10 m) • Reported EBIT: SEK -8 m (SEK -19 m) • Fully MDR CE-Certified portf
Slide 4: Strong market penetration pace in both geographic segments
Strong market penetration pace in both geographic segments • Strong progression in both geographic segments • Total antibiotic eluting CERAMENT grew (LTM) 220% versus Q4 2022 CBVF= CERAMENT Bone Void Filler CG = CERAMENT G (Gentamicin) CV = CERAMENT V (Vancomycin) 4
Slide 5: North America: Strong approval rate and market penetration for CERAMENT G
North America Strong approval rate and market penetration for CERAMENT G Q4 2023 • Sales of SEK 132 m, growth of 79% over Q4 2022, growth of 71% in constant exchange rate, CER • Sales in Q4 2023 represented a reported sequential growth of 9% over Q3 2023 • Impact from currency volatility in the quar
Slide 6: EUROW: Market share gains fuels sales performance
EUROW Market share gains fuels sales performance Q4 2023 • Sales of SEK 41 m, growth of 38% vs Q4 2022, 32% in constant exchange rates (CER) • Strong market dynamics – continued catch up of surgical back-log • Strong sales development reflecting market share gains Highlights • Full MDR CE-certificat
Slide 7: Financial Report
BONESUPPORT Q4 (2023) Report Financial Report
Slide 8: Q4 2023 net sales SEK 172.7 m
Q4 2023 net sales SEK 172.7 m SEK m • NA: 79 percent reported growth. 71 percent growth in CER • EUROW: 38 percent reported growth. 32 percent growth CER • High impact from currency movements 8
Slide 9: Gross Margin
North America +79% EUROW +38% (+71% CER) (+32% CER) Net sales Net sales Q4-23 Q4-23 North America 2023 2022 EUROW 2023 2022 SEK m Q4-23 Q3-23 Q2-23 Q1-23 Q4-22 SEK m Q4-23 Q3-23 Q2-23 Q1-23 Q4-22 Net Sales 131,6 121,0 103,9 85,9 73,4 Net Sales 41,1 37,2 36,5 33,8 29,8 Gross profit 125,1 114,4 98,2 8
Slide 10: Q4 expenses growth driven by commercial activity and strategic initiatives
Q4 expenses growth driven by commercial activity and strategic initiatives Key Figures 2023 2022 SEK m Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Selling expenses 59,6 53,5 55,0 49,0 46,8 38,8 37,4 35,2 Sales Commissions and fees 44,4 42,7 37,2 29,9 28,1 21,1 16,8 14,3 Research and Development expenses 17,5 12,5 14,6
Slide 11: A strong SEK having unfavorable impact in the period
A strong SEK having unfavorable impact in the period Key Figures 2023 2022 SEK m Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Net Sales 172,7 158,2 140,4 119,7 103,2 84,6 74,6 66,3 Gross Margin (%) 91,8 92,1 91,3 90,5 91,5 90,8 89,0 90,5 Operating profit -7,7 14,9 6,0 0,8 -19,3 -13,9 -14,9 -16,5 Adj. Operating profit (i
Slide 12: Clear Corporate Strategy Driving Value Creation
BONESUPPORT Q4 (2023) Report Clear Corporate Strategy Driving Value Creation
Slide 13: BONESUPPORT next chapter
BONESUPPORT next chapter Recap of Capital Markets Day Nov 28, 2023 • BONESUPPORT entering the Spinal fusion segment in US US Spine procedures: 750 k - Adding 750 k procedures of addressable market US Extremities - Entering with a strong value proposition: procedures: 380 k - 1/5 of spinal procedures
Slide 14: BONESUPPORT Q4 (2023) Report
BONESUPPORT Q4 (2023) Report • 67% sales growth • Continued success CERAMENT G USA • Extended label (trauma) submitted • TPT reimbursement 14